reolysin: Clinical Trials

20 trials of reolysin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed, 4 active not recruiting, 1 recruiting, 1 terminated. 20 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 220Completed 13, Active not recruiting 4, Recruiting 1, Terminated 1, Withdrawn 1
Phase 13Active not recruiting 2, Withdrawn 1

Follow reolysin: new trials by email Literature Review of reolysin trials Research Report on reolysin

Trials (filtered) newest first · largest first

All 20 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
Bevacizumab, FOLFIRI, Pelareorep - Ras-mutated Metastatic Colorectal Cancer, mCRC
Phase 2RecruitingOncolytics Biotech602026-04-302026-11-05
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial
Bortezomib, Dexamethasone, Pelareorep - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Phase 1 / Phase 2Active not recruitingUniversity of Southern California102022-10-072026-05-13
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
Pelareorep, Atezolizumab, Gemcitabine and nab-paclitaxel - Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified
Phase 1 / Phase 2Active not recruitingOncolytics Biotech1222021-10-272026-05-19
INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study
Pelareorep, Quality-of-Life Assessment, Questionnaire Administration - Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma
Phase 2Active not recruitingMridula George, MD252020-07-132025-04-04
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
Paclitaxel, Pelareorep, Avelumab - Breast Cancer Metastatic
Phase 2Active not recruitingOncolytics Biotech482020-06-102025-01-16
Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer
Pembrolizumab, Wild-type Reovirus - Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
Phase 2TerminatedNorthwestern University172018-11-142022-10-05
REO13 Melanoma With of Without GM-CSF
Reolysin, GM-CSF - Melanoma, Cancer of Skin
Phase 1 / Phase 2WithdrawnUniversity of Leeds2017-10-012018-05-04
A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer
Paclitaxel, Reolysin - Metastatic Breast Cancer
Phase 2CompletedCanadian Cancer Trials Group812013-02-202023-08-04
Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer
Docetaxel, Reolysin and Prednisone, Docetaxel and Prednisone - Prostate Cancer
Phase 2CompletedCanadian Cancer Trials Group852012-12-142023-08-04
Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy
Pemetrexed and Reolysin (and safety run-in), Pemetrexed, Docetaxel and Reolysin - Non Small Cell Lung Cancer
Phase 2CompletedCanadian Cancer Trials Group1662012-12-102023-08-04
Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer
Folfox plus Bevacizumab and reolysin, Folfox plus Bevacizumab - Colorectal Cancer
Phase 2CompletedCanadian Cancer Trials Group1092012-10-262023-08-23
Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Laboratory Biomarker Analysis, Paclitaxel, Pelareorep - Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Phase 2CompletedNational Cancer Institute (NCI)1082010-12-062020-09-16
Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel - Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma
Phase 2CompletedNational Cancer Institute (NCI)732010-12-012018-03-09
A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma
REOLYSIN, Gemcitabine - Metastatic Pancreatic Adenocarcinoma
Phase 2CompletedOncolytics Biotech342009-10-012015-04-10
A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung
REOLYSIN, Paclitaxel, Carboplatin - Metastatic or Recurrent Squamous Cell Carcinoma of the Lung
Phase 2CompletedOncolytics Biotech322009-10-012016-03-31
Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
REOLYSIN, Carboplatin, Paclitaxel - Metastatic Melanoma
Phase 2CompletedOncolytics Biotech142009-09-012015-04-10
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation
REOLYSIN®, Carboplatin, Paclitaxel - Carcinoma, Non-small Cell Lung
Phase 2CompletedOncolytics Biotech372009-03-012015-12-02
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma
REOLYSIN®, Carboplatin, Paclitaxel - Carcinoma, Squamous Cell of the Head and Neck
Phase 2CompletedOncolytics Biotech142008-08-012014-11-04
Viral Therapy in Treating Patients With Metastatic Melanoma
wild-type reovirus - Recurrent Melanoma, Stage IV Melanoma
Phase 2CompletedNational Cancer Institute (NCI)232008-04-012014-04-22
Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung
REOLYSIN® - Osteosarcoma, Ewing Sarcoma Family Tumors
Phase 2CompletedOncolytics Biotech532007-06-012014-10-02

Conditions studied

Carcinoma (3)  ·  Melanoma (3)  ·  Neoplasm Metastasis (3)  ·  Breast Neoplasms (2)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Pancreatic Neoplasms (2)  ·  Adenocarcinoma (1)  ·  Colorectal Neoplasms (1)  ·  Fallopian Tube Neoplasms (1)  ·  Fibrosarcoma (1)  ·  Histiocytoma, Malignant Fibrous (1)  ·  Leiomyosarcoma (1)  ·  Multiple Myeloma (1)  ·  Osteosarcoma (1)  ·  Ovarian Neoplasms (1)

Sponsors

Oncolytics Biotech (9)  ·  Canadian Cancer Trials Group (4)  ·  National Cancer Institute (NCI) (3)  ·  Mridula George, MD (1)  ·  Northwestern University (1)  ·  University of Leeds (1)  ·  University of Southern California (1)

Countries

United States (14)  ·  Canada (4)  ·  Germany (1)

Top investigators

Alain Mita, MD (1)  ·  Anne Noonan (1)  ·  Bernhard Eigl (1)  ·  David E Cohn (1)  ·  Derek Jonker (1)  ·  Devalingam Mahalingam (1)  ·  Devalingam Mahalingam, MD, PhD (1)  ·  Donald G Morris (1)  ·  Evanthia Galanis (1)  ·  Karl Mettinger, MD, PhD (1)  ·  Kevin R Kelly, MD (1)  ·  Miguel Villalona, MD (1)  ·  Monica Mita, MD (1)  ·  Mridula A George (1)  ·  Patricia Tang (1)

Results publications

PMID 26719427, PMID 27039845, PMID 29027598, PMID 29186319, PMID 29487723, PMID 29653857, PMID 29748010, PMID 37443348

NIH funding

N01CM00070 (2), N01CM62207 (1), P30CA014089 (1), P30CA016058 (1), P30CA060553 (1), P30CA072720 (1), U10CA027469 (1), U10CA180868 (1)